We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Global Framework Integrates Digital Pathology for Companion Diagnostic Development

By LabMedica International staff writers
Posted on 01 Jun 2026

Leica Biosystems (Nussloch, Germany) and CellCarta (Montreal, QC, Canada) have expanded a coordinated companion diagnostic (CDx) development model to biopharma sponsors worldwide. More...

Built on operational success in China, the flexible, end‑to‑end framework is designed to accommodate diverse regulatory pathways, evolving clinical data, and regional market requirements. The approach is further enabled by CellCarta’s CDx Bridge Model, which combines the speed of a single‑site approach with the scalability of a global laboratory network to help partners achieve faster market readiness while de‑risking complex programs.

At the core is a unified structure that aligns assay development, clinical trial execution, regulatory strategy, and commercial kit planning. By allowing parallel progression across investigational assay development, clinical testing, and future CDx commercialization, the model is intended to help sponsors adapt strategies in real time without resetting programs. It is also designed to maintain clinical timelines while incorporating emerging data, reduce duplicated work across stages, and establish a clearer, lower‑risk path to registration and commercialization.

Digital pathology integration is a key differentiator within the workflow, when appropriate. This capability is anchored in Leica Biosystems’ leadership in digital pathology, including its widely adopted Aperio Scanners (i.e., GT450) and IMS (HALO, HALO Dx) platform and an expanding AI‑enabled ecosystem. Combined with CellCarta’s experience implementing a globally standardized digital pathology platform for clinical trials, the collaboration aims to enable standardized, data‑driven pathology workflows, scalable image analysis across geographies, and consistent deployment of computational pathology in both clinical trials and diagnostic settings.

The partners state that embedding digital pathology directly into the development model strengthens assay performance and supports the advancement of data‑driven precision medicine. Overall, the expanded framework is intended to streamline development activities, support clinical timelines, and create a more efficient path from early‑stage assays to commercial diagnostics and global CDx availability.

“Leica Biosystems is committed to advancing cancer diagnostics and helping bring innovative companion precision therapies to patients more efficiently. By expanding our successful China joint development model globally with CellCarta, we can help biopharma sponsors connect clinical trial execution, regulatory planning, and commercial kit development in a more timely, coordinated, and cost-effective way,” said Karan Arora, SVP Advanced Assays, AI and Biopharma Partnerships, Leica Biosystems.

“Pharma sponsors are looking for a CDx commercialization path that is faster, more flexible, and more capital-efficient without compromising quality and regulatory rigor. Our work with Leica in China demonstrates how early alignment between the clinical trial assay and the future kit-development path can reduce rework, protect clinical timelines, and create a clear bridge from assay development to commercial CDx availability. Taking this collaborative model global is a natural extension of Leica Biosystems and CellCarta's partnership,” said Christopher Ung, Chief Scientific Business Officer at CellCarta.

Related Links
Leica Biosystems
CellCarta


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Nucleic Acid Purification Instrument
QIAsymphony Connect
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging

Menopause affects women across midlife and is often accompanied by endocrine changes, hot flashes, brain fog and sleep disturbances. Women spend roughly one third of their lives after the menopause transition,... Read more

Molecular Diagnostics

view channel
Image:(L to R) Co-first author Yuan Feng, PhD, corresponding author Xiaotu Ma, PhD, and co-first author Hanxia Li, PhD, all of the St. Jude Department of Computational Biology. (Photo courtesy of St. Jude Children\'s Research Hospital)

Genomic Profiling Predicts Relapse Risk by Subtype in Pediatric Leukemia

B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with more than 90% of patients surviving with modern treatments. Outcomes are worse when the disease returns, however, making... Read more

Hematology

view channel
Image: The newly certified products are the CytoCell ATM Deletion FISH Probe, CytoCell IGH Plus Breakapart FISH Probe, CytoCell IGH/FGFR3 Plus Translocation, Dual Fusion FISH Probe, and CytoCell IGH/MYEOV Plus Translocation, Dual Fusion FISH Probe. (Photo courtesy of OGT)

Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers

Hematological malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoid leukemia, and multiple myeloma require assessment of key cytogenetic abnormalities.... Read more

Immunology

view channel
Image: Study design and collection of lower respiratory tract lining fluid (RTLF) using the PExA instrument. (Aguilera K, Hober A, Greilert Norin N, et al. eBioMedicine, 2026. doi:10.1016/j.ebiom.2026.106538)

Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways

Respiratory viruses such as influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) require immune protection across the airway mucosa. Antibodies in the respiratory tract lining are important... Read more

Microbiology

view channel
Image: Four-quadrant streaking of fecal samples on chromogenic UTI agar shows various patterns of relative bacterial species abundance. The assorted shapes of the pinkish colonies indicate different E. coli strains. (Photo courtesy of Sokurenko Lab)

Stool Testing Predicts UTI Risk and Guides Antibiotic Selection

Urinary tract infections (UTIs) are a common reason for antibiotic prescribing in general medical practice and can be painful in postmenopausal women, sometimes progressing to kidney infection or life-threatening... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.